ENOblock synergizes with colistin to treat Acinetobacter baumannii infections
8
item.page.dc.date.issued
2025-01-01
item.page.dc.type
item.page.dc.identifier.issn
17574676
item.page.dc.identifier.eissn
17574684
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-105020313339
item.page.oaire.citation.title
EMBO Molecular Medicine
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
EMBO Molecular Medicine (2025)
punsarn.item.page.citation
Molina Panadero I., Moreno Rodríguez A., Rey Hidalgo A., de la Cruz M., Sánchez P., Tomás Gallardo L., Samernate T., Sencanski M., Glisic S., Genilloud O., Nonejuie P., Pérez-Pulido A.J., Hmadcha A., Smani Y. ENOblock synergizes with colistin to treat Acinetobacter baumannii infections. EMBO Molecular Medicine (2025). doi:10.1038/s44321-025-00331-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112947
item.page.dc.title
ENOblock synergizes with colistin to treat Acinetobacter baumannii infections
item.page.dc.contributor.correspondence
item.page.dc.contributor.other
item.page.dc.description.abstract
High-throughput screening studies provide an additional approach to discovering repurposed drugs for antimicrobial treatments. In this work, we report the identification of ENOblock, an anticancer drug, as an antimicrobial agent. We computationally and experimentally validated that ENOblock synergizes with colistin, the last resort antibiotic. Additionally, we identified enolase as the potential bacterial target for ENOblock. The in silico and in vitro antibacterial activity of ENOblock translated into potent in vivo efficacy in an animal infection model. Collectively, the preclinical data support the selection of ENOblock as a promising candidate for antimicrobial development, with the potential to address the urgent threat of infections caused by Acinetobacter baumannii.